ERBB2 and breast carcinoma: He et al. [77] developed a terpolymer-based NP (TRZ–TPN) for the targeted delivery of TRZ to BM in HER2-positive breast cancer, achieving high encapsulation efficiency while preserving antibody bioactivity.